Mettler-Toledo International (MTD) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jan, 2026Executive summary
Achieved strong Q4 2024 results with 12% local currency sales growth and 32% increase in adjusted EPS, driven by robust demand for Laboratory products, especially in Europe, and solid execution of margin improvement initiatives.
Maintained solid performance for full year 2024 despite soft market conditions, focusing on innovation, market leadership, and operational excellence.
Growth in 2025 will be driven by automation, digitalization, and high-growth areas to expand market share and earnings.
Financial highlights
Q4 2024 sales were $1.045 billion, up 12% year-over-year; gross margin improved to 61.2%, up 220 basis points.
Adjusted operating profit for Q4 was $351.9 million, up 25%; adjusted operating margin was 33.7%, up 360 basis points.
Adjusted EPS for Q4 was $12.41, a 32% increase; reported EPS was $11.96 vs. $8.52 prior year.
Full-year 2024 net sales grew 2% to $3.872 billion; adjusted operating profit was $1.2 billion, up 4%; adjusted EPS was $41.11, up 8%.
Adjusted free cash flow for 2024 was $900.6 million.
Outlook and guidance
2025 guidance assumes continued market uncertainty and geopolitical risks, with gradual improvement expected.
Q1 2025 local currency sales expected to decline 3%-4%; adjusted EPS $7.75-$7.95, down 11%-13%.
Full-year 2025 local currency sales growth forecast at 3%; adjusted EPS $42.35-$43, up 3%-5%.
Guidance includes headwinds from prior shipping delays and adverse currency impacts.
Free cash flow expected at $860 million; share repurchases at $875 million.
Latest events from Mettler-Toledo International
- Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026 - Director elections, auditor ratification, and say-on-pay vote set for May 7, 2026.MTD
Proxy Filing18 Mar 2026 - Q4 2025 saw 8% sales and EPS growth, with a strong 2026 outlook despite market headwinds.MTD
Q4 20256 Feb 2026 - Q2 sales fell 4%, but margin gains and service growth led to raised full-year guidance.MTD
Q2 20242 Feb 2026 - Q3 adjusted EPS up 4% on 1% sales growth; Laboratory and Service led gains amid soft markets.MTD
Q3 202415 Jan 2026 - Manufacturing flexibility, innovation, and operational programs drive growth and margin expansion.MTD
Stifel 2024 Healthcare Conference13 Jan 2026 - Innovation, digitalization, and margin expansion fuel global growth and shareholder value.MTD
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Lab and service growth offset China industrial softness; cautious 2025 outlook with service focus.MTD
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Innovation, digitalization, and service drive growth, with margin expansion and 2025 recovery expected.MTD
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026